Implications of personalized medicine—perspective from a cancer center

Three advances are dramatically changing the landscape of oncology. First, hundreds of drugs are available that inhibit targets involved in oncogenesis. Second, efforts to reclassify malignant diseases are expanding the number of orphan molecular diseases. Third, the implementation of high-throughput technologies will allow risk of relapse prediction and drug sensitivity. Patients predicted to relapse will be referred to comprehensive cancer centers where new drugs will be tested. It is anticipated that a high number of small, biology-driven clinical trials will report high sensitivity to targeted agents in rare biologically defined diseases. Drug registration and biomarker analysis needs to be revisited to avoid large phase III trials with control arms. The use of high-throughput technologies will lead to the development of virtual cells. These considerations highlight the need for developing a consortium of comprehensive cancer centers to run clinical trials in rare, molecularly-defined populations, and implement high-throughput technologies for daily practice.

[1]  Lee T. Sam,et al.  Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.

[2]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[3]  Emerging Approaches in Molecular Profiling Affecting Oncology Drug Discovery , 2005 .

[4]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[5]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[6]  Des Powe,et al.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.

[7]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[8]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[9]  Lajos Pusztai,et al.  Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.

[10]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[11]  M. Ratain,et al.  Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[13]  R. Rosell,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer , 2010, Current opinion in oncology.

[14]  R. Strausberg,et al.  Whole-genome cancer analysis as an approach to deeper understanding of tumour biology , 2009, British Journal of Cancer.

[15]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[16]  A. Kurian.  BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications , 2010, Current opinion in obstetrics & gynecology.

[17]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[18]  A. Emley,et al.  RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis , 2009, The British journal of dermatology.

[19]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[20]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[21]  David I. Smith,et al.  Tumor Transcriptome Sequencing Reveals Allelic Expression Imbalances Associated with Copy Number Alterations , 2010, PloS one.

[22]  T. Mukohara,et al.  Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  안성민.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2011 .

[24]  Michael Williams,et al.  Overview of Drug Discovery and Development , 2006, Current protocols in pharmacology.

[25]  J. Williams.  Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. , 2003, Drug news & perspectives.

[26]  S. Kobayashi,et al.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. , 2009, Clinical lung cancer.

[27]  Richard J. K. Taylor,et al.  Long-term survival of women with breast cancer in New South Wales. , 2003, European journal of cancer.

[28]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[29]  G. Hortobagyi,et al.  Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers , 2008 .

[30]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[31]  C. Desmedt,et al.  Gene expression predictors in breast cancer: current status, limitations and perspectives. , 2008, European journal of cancer.

[32]  C. Perou,et al.  TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .

[33]  A. Goldhirsch,et al.  Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[35]  Brian J. Stevenson,et al.  Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line , 2009, Proceedings of the National Academy of Sciences.

[36]  J. Garcia-conde,et al.  p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer , 2006, Clinical Cancer Research.

[37]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[39]  J. Rothberg,et al.  Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.